Financial Performance - Q2 2025 revenue was $138.1 million, a 0.1% increase year-over-year[26, 48] - GAAP gross margin was 43.1% in Q2 2025, a decrease of 0.7% compared to Q2 2024's 43.8%[30, 48] - Non-GAAP gross margin was 47.7% in Q2 2025, a decrease of 1.3% compared to Q2 2024's 49.0%[30, 48] - GAAP operating loss improved to $16.6 million in Q2 2025 from $26.0 million in Q2 2024[36, 48] - Non-GAAP operating income was $1.1 million in Q2 2025, compared to a loss of $3.2 million in Q2 2024[36, 48] - GAAP net loss improved to $16.7 million in Q2 2025 from $25.7 million in Q2 2024[36, 48] - Non-GAAP net income was $2.2 million in Q2 2025, compared to a loss of $3.0 million in Q2 2024[36, 48] Balance Sheet and Cash Flow - The company's cash and cash equivalents and short-term deposits were $254.6 million in Q2 2025[39] - Net working capital was $448.8 million in Q2 2025[39] - Cash flow from operating activities was negative $1.1 million in Q2 2025[38] Outlook - The company expects full-year 2025 revenue between $550 million and $560 million[42] - The company expects full-year 2025 non-GAAP gross margins between 46.7% and 47.0%[42] - The company expects full-year 2025 non-GAAP operating expenses between $248 million and $251 million[42]

Financial Performance - Q2 2025 consolidated revenue was $95 million, reflecting an 8% QoQ rebound excluding Geomagic[29] - Medical Technologies revenue grew 13% YoY and 16% QoQ, representing over $80 million of FY'24 revenues[19] - The company achieved significant OpEx reductions of $17 million YoY and $15 million QoQ[35] - Net income for Q2 2025 was $1044 million, with GAAP EPS at $057[39] - The company expects to exit Q4'25 with operating expenses in the low $40 million range[13] Strategic Initiatives - The company completed the sale of the Geomagic business for nearly $120 million in cash on April 1, 2025[10, 44] - A debt transaction in June permanently retired $88 million in debt and refinanced $92 million through 2030, along with repurchasing 8 million common shares[10, 44] - Cost reduction and profitability improvement initiatives target over $85 million of annualized savings planned through 1H'26[12] Balance Sheet - The company ended the quarter with approximately $134 million in cash, cash equivalents, and restricted cash[44] - As of August 2025, the company's global cash, cash equivalents, and restricted cash amounted to approximately $130 million[44]

As filed with the Securities and Exchange Commission on August 6, 2025. Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Velo3D, Inc. (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporation or organization) (Primary Standard Industrial Classification Code Number) Delaware 3559 98-1556965 (I.R.S. Employer Identification Number) 2710 Lakeview Court Fremont, ...

Financial Data and Key Metrics Changes - Revenue reached $241 million, representing reported revenue growth of 2% and organic revenue declines of 2% [7] - Adjusted gross margins held at 46% and adjusted EBITDA margin was 22%, both in line with expectations [8][29] - Non-GAAP adjusted earnings per share was $0.76, up 4% versus the prior year [29] - Operating cash flow for the quarter was $15 million compared to $41 million in the prior year, primarily driven by timing of tax payments and increased inventory purchases [29][30] Business Line Data and Key Metrics Changes - New product revenue grew by over 50% year over year, with a vitality index climbing to 21% of total sales [33] - Advanced surgery business experienced 17% growth year over year, driven by strong patient procedural growth rates [35] - Robotics and automation business unit revenue was up nearly 16% year over year, with a book to bill ratio of 1.05 [34] - Precision medicine business saw a 13% decline in sales year over year, but grew 10% sequentially [35] Market Data and Key Metrics Changes - Sales to medical device markets remained strong, driving sustained double-digit growth in advanced surgery [11] - Sales to industrial capital equipment saw declines year over year, but revenue has stabilized and bookings are rising at a double-digit pace [18] - Total China sales were up 15% year over year, despite challenges related to tariffs [80] Company Strategy and Development Direction - Long-term growth strategy focuses on markets with secular tailwinds such as precision and AI-driven robotics, minimally invasive surgery, and precision medicine [10] - The company aims to expand its portfolio into high-growth areas, increasing recurring consumables revenue to approximately 15% of sales [11] - The acquisition of Keon Technologies is expected to enhance the company's capabilities in RFID and AI-enhanced cloud-based software [30][23] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving $50 million of incremental new product revenue for 2025, mainly due to strong outlook for next-generation medical devices [12] - The company is optimistic about the growth in physical AI applications, expecting sales to double in 2026 versus 2025 [15] - Management acknowledged the impact of tariffs but indicated that mitigation strategies are in place, with a focus on regional manufacturing [37][40] Other Important Information - The company expects full-year 2025 GAAP revenue to be approximately $970 million to $985 million, representing overall revenue growth of 2% to 4% [41] - Adjusted EBITDA for the full year of 2025 is expected to be $225 million to $230 million, or approximately a 23% EBITDA margin [42] - The company has a strong balance sheet and credit facility, positioning it well for future acquisitions [47] Q&A Session Summary Question: Can you break down your revenue guidance? - The full year guidance indicates reported organic growth will likely be down 1% to up 1% [53] Question: What is the FX implied impact for benefit? - The FX impact is expected to carry forward from the second quarter [55] Question: What are the biggest drivers of organic growth in 2026? - Key drivers include advanced surgery product ramps, physical AI applications, and strong design wins [60][64] Question: Have we seen the low point for the year in industrial and precision medicine? - Management believes the industrial business has reached its bottom and will improve sequentially [72] Question: What is the status of the $35 million held up due to tariffs? - This amount is factored into guidance, and recovery is not assumed yet [79] Question: Can you elaborate on the warehouse robotics win? - The technology involves sensing and fast, safe reactions, essential for advanced warehouse automation [90]

Core Viewpoint - 3D Systems is set to release its financial results for the second quarter of 2025 on August 11, 2025, after U.S. stock markets close, followed by a conference call on August 12, 2025, at 8:30 a.m. Eastern Time [1][2]. Group 1 - The financial results will be discussed in a conference call and webcast, which can be accessed via the company's investor relations website [2]. - The company has a long history of nearly 40 years in the 3D printing and additive manufacturing industry, founded by Chuck Hull [3]. - 3D Systems provides industry-leading 3D printing technologies, materials, and software across various high-value markets, including medical, aerospace, and AI infrastructure [3].

Core Viewpoint - Velo3D, Inc. is set to release its second quarter 2025 financial results on August 6, 2025, and will host a conference call to discuss these results [1][2]. Company Overview - Velo3D is a leading US-based metal 3D printing technology company that specializes in additive manufacturing (AM) [4]. - The company has developed solutions that overcome the limitations of legacy metal AM, allowing for the design and production of high-value metal parts [5]. - Velo3D's technology is utilized in various industries, including space exploration, aviation, power generation, energy, and semiconductors, enabling the creation of mission-critical components [5]. Technology and Innovation - The company's integrated solution includes Flow print preparation software, the Sapphire family of printers, and the Assure quality control system, all powered by Velo3D's Intelligent Fusion manufacturing process [5]. - Velo3D has been recognized as one of Fast Company's Most Innovative Companies for 2023, highlighting its impact on the industry [5].

Financial Data and Key Metrics Changes - Total consolidated revenue decreased year over year by 5.8% to €64.8 million, despite strong performance in the Medical segment [20][23] - Gross profit margin increased to 58.3%, reflecting changes in revenue mix and optimization of production costs [20][31] - Adjusted EBIT for the quarter amounted to €3.1 million, showing a strong increase compared to prior quarters [20][25] - Net result for the quarter was a profit of €0.2 million, impacted by unfavorable exchange rate fluctuations [20][33] - Free cash flow was positive, leading to a net cash position of €63 million at the end of Q2, an increase of €2 million since the beginning of the year [20][35] Business Line Data and Key Metrics Changes - Medical segment achieved high double-digit growth, with revenue increasing by almost 17% this quarter [20][26] - Software segment revenue decreased by 12% to €9.9 million, partly due to the transition to a recurring revenue model and macroeconomic pressures [20][27] - Manufacturing segment revenue declined by almost 25% compared to the same period last year, realizing quarterly revenue of €22.1 million [20][29] Market Data and Key Metrics Changes - Materialise Medical accounted for 51% of total revenue, Materialise Software for 15%, and Materialise Manufacturing for 34% in Q2 [23] - The U.S. market continued to face challenges, impacting sales volumes in the Software segment [27][61] Company Strategy and Development Direction - The company is focusing on mass personalization in the medical business, expanding into new markets such as respiratory [7][8] - A pilot collaboration with Johnson & Johnson aims to advance the adoption of surgical planning solutions in the respiratory market [11] - The company is engaging with the defense sector to enhance regional defense capabilities, which is expected to open new opportunities [15][16] Management Comments on Operating Environment and Future Outlook - Management anticipates that geopolitical volatility and macroeconomic uncertainty may intensify, impacting the business climate for the remainder of the year [37] - Revenue guidance for the full year has been slightly reduced from €270 million - €285 million to €265 million - €280 million [38] - Despite the lower revenue outlook, management remains confident in the fundamentals of the business and the potential for structural cost efficiencies [38] Other Important Information - The company continues to invest in R&D, with over €11 million spent in the quarter, primarily in the Medical segment [32] - A restructuring in the manufacturing division has been implemented to manage costs amid revenue pressures [19][30] Q&A Session Summary Question: Can you quantify the opportunity in the respiratory market? - Management indicated that the respiratory market is new and still developing, with revenue impact not expected until next year [44][45] Question: What is the purpose of the €20 million debt taken out during the quarter? - This debt is part of an earlier agreement for a €50 million facility, intended for CapEx or M&A investments in the future [47][49] Question: What drove the strong gross margins despite lower revenues? - The strong gross margins were attributed to a combination of mix effects and the ability to reduce production costs in both medical and manufacturing segments [50] Question: Will the medical segment continue to see double-digit growth? - Management expressed confidence that the medical segment will continue to grow, with ongoing investments in new markets [58] Question: What parameters were used for the revised top-line guidance? - The revised guidance was based on a detailed exercise considering various business lines and market conditions, rather than a single parameter [60][62]

Company Overview - Northann Corp. is a leader in additive manufacturing and 3D printing technologies for the building materials industry, founded in 2022 and headquartered in Fort Lawn, South Carolina [2] - The company offers innovative flooring, decking, and other construction products through its flagship brand, Benchwick [2] - Northann holds a robust portfolio of over 60 granted or pending patents, highlighting its commitment to innovation and sustainability [2] Financial Disclosure - Northann Corp. disclosed in its annual report on Form 10-K for the fiscal year ended December 31, 2024, that the audit opinion contained a going concern qualification from its independent registered public accounting firm [1] - This announcement was made to comply with NYSE American Company Guide Sections 401(h) and 610(b), requiring separate disclosure of such audit opinions [1] - The announcement does not represent any change or amendment to the company's 2024 audited financial statements or its 2024 annual report on Form 10-K [1]

Core Insights - The 2025 Additive Manufacturing Competition, co-sponsored by SME and Stratasys, showcased the talents of students in additive manufacturing technologies during the SkillsUSA National Leadership and Skills Conference [2][4] - The competition aimed to educate students about additive manufacturing while providing hands-on experience applicable to real-world products [4][5] - This year marked the introduction of middle school students to the competition, expanding its reach to younger participants [7] Competition Overview - A total of 100 students from 39 states participated, representing three middle schools, 34 high schools, and 13 post-secondary institutions [4] - Nearly 500 parts were printed using Stratasys 3D printers during the three-day event [4] - The competition challenged students to design and prototype electric vehicles using additive manufacturing, focusing on sustainable transportation [8] Awards and Recognition - Winning teams received gold, silver, and bronze medals along with scholarships of $1,500, $1,000, and $500 from the SME Education Foundation [9] - Gold and silver medalists were awarded professional-grade Prusa MK3S 3D printer kits, while bronze medalists received mini 3D printers [9] - Middle school winners received UltiMaker Sketch 3D printers and all participants received gift bags related to additive manufacturing [10] Certification and Skills Development - 94 students took the Additive Manufacturing Fundamentals Certification Exam, with a pass rate of 67% [13] - Each student received a bundle of 20 Tooling U-SME classes valued at nearly $400 to prepare for the exam [13] - The competition emphasizes critical thinking, creativity, and technical skills, preparing students for careers in manufacturing [14] Industry Impact - The partnership between SME and Stratasys aims to invest in the future of additive manufacturing and foster innovation among students [13] - The competition serves as a platform for students to engage with cutting-edge tools and real-world challenges in manufacturing [5][14] - The involvement of industry leaders like Autodesk, SolidWorks, and UltiMaker highlights the collaborative effort to enhance education in advanced manufacturing [2][5]

Core Viewpoint - 3D Systems has successfully completed strategic transactions to refinance its outstanding convertible notes and repurchase shares, enhancing its capital structure and financial flexibility [1][4]. Group 1: Financial Transactions - The company repurchased approximately 8 million shares of its common stock, representing about 6% of its outstanding shares as of May 2, 2025 [1][7]. - The refinancing involved retiring approximately $88 million of debt, which is 41% of the prior balance, at a significant discount to par [7]. - The company issued $92 million in new Convertible Senior Secured Notes due in 2030, with an interest rate of 5.875% per annum [2][7]. Group 2: Financial Impact - The repurchase of existing notes at a discount is expected to result in a gain of approximately $10 million in the second quarter financial statements [3]. - The transactions are anticipated to reduce overall outstanding debt and extend the maturity profile, providing enhanced financial flexibility [4][7]. Group 3: Management Commentary - Dr. Jeffrey Graves, president and CEO, emphasized that these transactions are a significant step in strengthening the company's capital structure and managing potential dilution through share repurchase [4]. - The company has reduced its total debt by over 72% since 2021 through opportunistic transactions [4]. Group 4: Future Outlook - The company maintains strong cash reserves to support ongoing restructuring efforts and key growth initiatives [7]. - The new notes will mature on June 15, 2030, unless converted or repurchased earlier, reflecting a strategic move to manage debt maturity [2][7].